TP53 and myelodysplastic syndrome: The most heavily investigated and targeted agent for patients with TP53‐mutant MDS and AML has been APR‐246 (eprenetapopt), a p53 reactivator, in combination with azacitidine, but also in triplets with venetoclax.113, 114